The Latest Breaking News from GSK

Why Did FDA Pull Authorization For GSK-Vir's COVID-19 Therapy? Read Here

The U.S. health regulator said GlaxoSmithKline Plc (NYSE:GSK) and Vir Biotechnology Inc's (NASDAQ:VIR) antibody therapy was no longer authorized as a COVID-19 treatment. The decision was made as the CDC now estimates that the proportion of Covid-19 cases caused by BA.2 is above 50% nationwide. "Sotrovimab is no longer authorized to treat COVID-19 in any…

Benzinga · Apr 6, 2022

Governments want COVID vaccine developers to aim higher in hunt for better shots

As governments prepare to live with COVID-19, some are questioning how much to rely on drugmakers to adapt vaccines to ward off future virus variants amid signs of tension between companies and regulators over the best approach, according to several sources familiar with the matter.

Reuters · Mar 31, 2022

CureVac - GSK Start Dosing In Next-Gen COVID-19 Vaccine Candidate Trial

CureVac N.V. (NASDAQ:CVAC) dosed the first participant in a Phase 1 study of COVID-19 second-generation mRNA vaccine candidate, CV2CoV, developed with GlaxoSmithKline plc (NYSE:GSK).  The clinical trial is expected to provide valuable data to evaluate further the performance of CureVac’s second-generation mRNA backbone, which has the potential to be applied broadly in future vaccines against…

Benzinga · Mar 30, 2022

LifeMine Therapeutics, GSK Ink $70M Drug Discovery, Development Pact

LifeMine Therapeutics Inc, a drug discovery startup that uses genetically-encoded small molecules, has partnered with GlaxoSmithKline plc (NYSE:GSK) to discover and develop drugs from fungal genomes.  GSK will bring three targets for LifeMine to run through its proprietary drug discovery platform, which scans for fungi that could be a match to create a…

Benzinga · Mar 23, 2022

Workers at GSK to vote on possible strike action over pay offer

Around 150 workers at the company's plant in Barnard Castle have rejected a 4% pay offer

Birmingham Post · Mar 21, 2022

GlaxoSmithKline says it will not start any new clinical trials in Russia

Pharma firm joins AstraZeneca and Pfizer in saying it will not enrol new patients into studies

The Guardian - UK · Mar 17, 2022

GSK halts new clinical trials in Russia but continues supply of medicines

The company is the latest drug-maker to take such steps, although the healthcare sector has not pulled out of the region entirely.

The Independent UK · Mar 17, 2022

Europe Kickstarts Reviewing AstraZeneca Application For Its COVID Antibody

European Medicines Agency has started reviewing AstraZeneca Plc's (NASDAQ:AZN) application for antibody-based COVID-19 therapy but gave no timeline for a conclusion. Infections from COVID-19 are still rising in parts of the world, including Europe. On Tuesday, China posted a steep jump in daily COVID-19 infections, with new cases more than doubling from a…

Benzinga · Mar 16, 2022

GSK/Vir Biotech's COVID-19 Antibody Associated With Resistance Mutations, New Research Shows

According to new research in Australia, some people have developed sotrovimab-resistant mutations following infusions with the GlaxoSmithKline Plc (NYSE:GSK) and Vir Biotechnology Inc (NASDAQ:VIR) monoclonal antibody with COVID-19 infection. Data shows that the mutations have been associated with a reduction by a factor of 100 to 297 in neutralization by sotrovimab. "These data show the persistence…

Benzinga · Mar 11, 2022

BP and Shell lead rush to exit Russia. There can be no going back

Oil is always a political business, and there’s no point pretending otherwise

The Guardian - UK · Feb 28, 2022